Do High Drug Prices Drive Innovation, Or Hurt It?
In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.
Dr. Bach responds with two primary points:
1) The argument Dr. LaMattina presents is chosen from a pick-list of rationales for high pricing because it loosely fits the scenario.
2) The post hoc rationale for Gilead's pricing undercuts a core principle related to the value of innovation that is not transferred back to the innovators but instead goes to society.
Read the full article here.